中国医学创新2024，Vol.21Issue(17)：59-62,4.DOI:10.3969/j.issn.1674-4985.2024.17.014
贝伐珠单抗结合TC化疗方案治疗卵巢癌的临床效果及对血清炎症因子、肿瘤标志物的影响
Clinical Effect of Bevacizumab Combined with TC Chemotherapy Regimen in the Treatment of Ovarian Carcinoma and Its Influence on Serum Inflammatory Factors and Tumor Markers
程晓波 1杨勤 1王蕾 1杨莉 1郭嫣1
作者信息
- 1. 当阳市人民医院肿瘤科 湖北 当阳 444100
- 折叠
摘要
Abstract
Objective:To explore the effect of of Bevacizumab combined with TC chemotherapy regimen in the clinical treatment of ovarian carcinoma and its influence on serum inflammatory factors and tumor markers.Method:A total of 92 patients with ovarian carcinoma treated in Department of Oncology,Dangyang People's Hospital from April 2018 to April 2020 were selected and divided into control group(n=46)and observation group(n=46)by random number table method.The control group was treated with conventional TC chemotherapy regimen,and the observation group was treated with Bevacizumab based on the control group.The survival rate,recurrence rate,tumor markers levels and serum inflammatory factors levels were compared between the two groups.Result:The 1-year and 3-year survival rates of observation group were higher than those of control group(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and neuron specific enolase(NSE)in observation group were lower than those in control group(P<0.05).After treatment,the levels of C reactive protein(CRP),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)in observation group were lower than those in control group(P<0.05).Conclusion:In the treatment of ovarian carcinoma,Bevacizumab combined with TC chemotherapy regimen has good clinical effect,which can effectively improve the survival rate of patients,improve the levels of tumor markers,and reduce the levels of serum inflammatory factors.关键词
贝伐珠单抗/TC化疗方案/卵巢癌/炎症因子/肿瘤标志物Key words
Bevacizumab/TC chemotherapy regimen/Ovarian carcinoma/Inflammatory factors/Tumor markers引用本文复制引用
程晓波,杨勤,王蕾,杨莉,郭嫣..贝伐珠单抗结合TC化疗方案治疗卵巢癌的临床效果及对血清炎症因子、肿瘤标志物的影响[J].中国医学创新,2024,21(17):59-62,4.
